Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

The estimated patent date of Remicade and Rituxan

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
rwdm Member Profile
 
Followed By 2
Posts 72
Boards Moderated 0
Alias Born 07/19/10
160x600 placeholder
Top Equities Stories of the Day
e>

U.S. healthcare group Danaher Corp. said Monday it will acquire Swiss dental-implant maker Nobel Biocare Holding AG in a cash deal worth about $2.1 billion, to strengthen its position in the dental market. (published 0559 GMT)

Don't Underestimate Smartwatches
U.S. Hot Stocks: Hot Stocks to Watch
Sterling Steady as Scottish 'No' Camp Regains Lead--Update
Asian Shares Rise as Nikkei Pushes Higher
Intel Unveils Latest Xeon Server Chip -- Update
U.S., EU Widen Sanctions on Russia
Americans Support Striking Islamic Militants, Poll Shows
Sirius XM Increases 2014 Subscriber Guidance, Citing Strong Summer Car Sales
Europe Markets Pull Back As Scottish Poll Spooks Investors
rwdm   Thursday, 07/29/10 02:07:10 PM
Re: None
Post # of 181893 
The estimated patent date of Remicade and Rituxan in Europe are 2014 and 2015 respectively. In the US both expiry dates are in 2018. Is this because of Genentech's Cabily patent? If yes, does this mean that the expiry date of most of the mabs in US is 2018?

Is Teva's Rituximab TL011, which is starting nowadays clinical trials, in the regulatory pathway of BLA or as a biosimilar?

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist